300705 Hunan Jiudian Pharmaceutical
- 25.45
- -0.35-1.36%
Hunan Jiudian Pharmaceutical News
Jiudian Pharmaceutical (300705.SZ): Ifluprofen patch approved for clinical trials
Gelonghui, May 22丨Jiudian Pharmaceutical (300705.SZ) announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. The ifluprofen patch was approved to carry out clinical trials for osteoarthritis pain relief, and clinical trial research will be carried out after completing relevant preparations.
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Jiudian Pharmaceutical (300705.SZ): Jiao Qi Musk Gel Patch completed the declared production in December 2023 and is expected to be approved in 2025
Gelonghui, May 21丨Jiudian Pharmaceutical (300705.SZ) recently received a survey on “Expected marketing time and promotion plan for the traditional Chinese medicine gel paste pepper Qimusk?” The company replied that the production of Jiaoqi Musk Gel Patch has been declared for production in December 2023 and is expected to be approved in 2025. The sales channels for this product are still mainly in-hospital channels. The focus is on supporting hospital development, hoping to set it as a benchmark for new traditional Chinese medicine pastes.
Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) is abou
Jiudian Pharmaceutical (300705.SZ): 2023 equity distribution 10 to 4 installments of 3.21 yuan Equity Registration Date May 23
Gelonghui announced on May 16, 丨 Jiudian Pharmaceutical (300705.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 3.2,100 in cash (tax included) to all shareholders for every 10 shares based on the total share capital registration date when the company implemented the 2023 profit distribution and capital transfer plan from the capital reserve fund. At the same time, the capital reserve fund was used to transfer 4 shares for every 10 shares to all shareholders. The share registration date for this equity distribution is May 23, 2024, and the ex-dividend date is May 24, 2024.
Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' It's only natural to co
Jiudian Pharmaceutical (300705.SZ) announced its 2023 annual results. Net profit of 368 million yuan increased 36.54% year over year
Jiudian Pharmaceutical (300705.SZ) released its 2023 annual performance report. The company achieved operating income during the reporting period...
Hunan Jiudian Pharmaceutical Co., Ltd.'s (SZSE:300705) Stock Is Going Strong: Is the Market Following Fundamentals?
Hunan Jiudian Pharmaceutical (SZSE:300705) has had a great run on the share market with its stock up by a significant 11% over the last three months. Given the company's impressive performance, we d
Hunan Jiudian Pharmaceutical Co., Ltd.'s (SZSE:300705) Market Cap Increased by CN¥414m, Insiders Receive a 48% Cut
Key Insights Hunan Jiudian Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion 52% of the business is held by the top 4 shareholders Institutional ow
Jiudian Pharmaceutical (300705.SZ): There are no export plans for topical pharmaceutical products
Gelonghui March 18 丨 Jiudian Pharmaceutical (300705.SZ) said at an investor relations event that the company has no export plans for topical pharmaceutical products.
Jiudian Pharmaceutical (300705.SZ): Judging from the implementation in Guangdong Province and Henan Province, the exchange of price for volume has been achieved relatively well
Gelonghui, March 18 | Jiudian Pharmaceutical (300705.SZ) said at an investor relations event that the collection of loxoprofen sodium gel patches has basically been carried out in the Guangdong Union region. Judging from the implementation in Guangdong Province and Henan Province, the exchange of price for volume has been achieved quite well. The collection of loxoprofen sodium gel patch in Zhejiang Province has not yet been implemented. The company expects to further expand the sales scope of this product after implementation, increase its market share, enhance the company's brand influence, and have a positive impact on the company's long-term development. Loxoprofen sodium gel patch is currently only available in the Beijing-Tianjin-Hebei “3+N” Alliance Drug Centralized Procurement Alliance provinces
Jiudian Pharmaceutical (300705.SZ): The out-of-hospital market price of loxoprofen sodium gel patch is basically consistent with the in-hospital market price
On March 11, Ge Longhui | Jiudian Pharmaceutical (300705.SZ) was surveyed by a specific target on March 11, 2024, about “How much is the unit price of loxoprofen sodium gel paste in hospital and out of hospital? ”, the company replied that the price of three packs of loxoprofen sodium gel patch was 72.8 yuan, the winning bid price for the Guangdong Union region was 18.19 yuan/stick, the winning bid price for Zhejiang Province was 17.37 yuan/stick, and the winning bid price for the Beijing-Tianjin-Hebei “3+N” Alliance region was 18.19 yuan/stick. The out-of-hospital market price of loxoprofen sodium gel patch is basically consistent with the in-hospital market price.
Risks To Shareholder Returns Are Elevated At These Prices For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705)
There wouldn't be many who think Hunan Jiudian Pharmaceutical Co., Ltd.'s (SZSE:300705) price-to-earnings (or "P/E") ratio of 32.2x is worth a mention when the median P/E in China is similar at about
Jiudian Pharmaceutical (300705.SZ): Signed an antibacterial and anti-inflammatory peptide patent and technology transfer agreement
On February 28, Gelonghui Pharmaceutical (300705.SZ) announced that the company signed an antibacterial and anti-inflammatory peptide patent and technology transfer agreement with Hunan Zhongsheng Quanpeptide Biotechnology Co., Ltd. (“Zhongsheng Quanpeptide”) to introduce its related technology and patents. The total transfer cost of this transaction did not exceed RMB 560 million (of which the total milestone cost did not exceed RMB 60 million, and the net sales share after commercialization of the product was no more than RMB 500 million).
Jiudian Pharmaceutical (300705.SZ): Currently, the company has no plans to repurchase shares
Gelonghui, Feb. 22丨Jiudian Pharmaceutical (300705.SZ) said during an investigation by a specific target that the company currently has no plans to repurchase shares, and if there are any relevant plans in the future, the company will promptly fulfill its obligation to disclose information.
Jiudian Pharmaceutical (300705.SZ): Loxoprofen sodium gel patch is mainly sold at the hospital side, and the proportion of outside the hospital is relatively small
On February 22, Ge Longhui Pharmaceutical (300705.SZ) said during a survey of specific subjects that loxoprofen sodium gel patches are mainly sold on the hospital side, and the proportion of outside the hospital is relatively small. In the future, the company will increase investment from outside the hospital, build the “Jiuyue” cream brand, and enhance brand value.
Jiudian Pharmaceutical (300705.SZ): E-commerce companies mainly sell on Jingdong Pharmacy, Ali Health and the company's own applets
Gelonghui, Feb. 22丨Jiudian Pharmaceutical (300705.SZ) said during a survey of specific subjects that e-commerce companies mainly sell on Jingdong Pharmacy, Ali Health and the company's own mini-programs. Both channels have achieved good growth.
Jiudian Pharmaceutical (300705.SZ): As national and provincial collection progresses, the sales cost of collected varieties will be drastically reduced
Gelonghui February 20 丨 Jiudian Pharmaceutical (300705.SZ) said at an investor relations event that with the advancement of national and provincial collection, sales expenses for collected varieties will be drastically reduced. The market for the company's topical formulations is gradually entering a mature period, and related expenses will be reduced. At the same time, the company is undergoing a transformation to a semi-self-operated model, which will also further reduce the sales expense ratio.
Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortun
Jiudian Pharmaceutical (300705.SZ): The company hopes to continue to maintain a certain level of growth in 2024
Gelonghui January 30 丨 Some investors asked Jiudian Pharmaceutical (300705.SZ): What are the company's performance expectations for 2024? Jiudian Pharmaceutical replied: From January to September 2023, the company achieved operating income of 1,893 million yuan, an increase of 18.37% over the same period last year; realized net profit attributable to shareholders of listed companies of 310 million yuan, an increase of 48.76% over the same period last year. The company hopes to maintain a certain level of growth in 2024. Please pay attention to the company's budget announcements at that time.
Analysis
Price Target
No Data
